Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 21, 2018
Pharmacy Choice - News - Drug Delivery Systems - May 21, 2018

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 93     Next >>     Go To Page:

5/21/18 - Active Implantable Medical Device Market: Technological Leap In Healthcare Industry 2018 - 2025
According to a new report published by Reports Monitor titled, "Active Implantable Medical Device Market by Product Type, Procedure and End-User: Global Opportunity Analysis and Industry Forecast, 2017-2025," the Active Implantable Medical Device Market is growing rapidly from 2017 to 2025.. In last decade healthcare sector has grown tremendously o
5/21/18 - Active Implantable Medical Device Market: Technological Leap In Healthcare Industry 2018 2025
"Active Implantable Medical Device Market" According to a new report published by Reports Monitor titled, " Active Implantable Medical Device Market by Product Type, Procedure and End-User: Global Opportunity Analysis and Industry Forecast, 2017-2025," the Active Implantable Medical Device Market is growing rapidly from 2017 to 2025.. In last decad
5/21/18 - Barbara Taylor, Senior Director of Marketing for Portal Instruments, to Speak at Drug Delivery West in San Francisco
Portal Instruments, a medical device company focused on advanced drug delivery and solving the challenge of self-administering biological medicines, is pleased to announce that Senior Director of Marketing Barbara Taylor will be speaking at the inaugural Drug Delivery West program in San Francisco, taking place May 21-22. Taylor will present...
5/21/18 - FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
SILVER SPRING, Md., May 21, 2018/ PRNewswire-USNewswire/ The U.S. Food and Drug Administration today approved Doptelet tablets to treat low blood platelet count in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use. "Patients with chronic liver dis
5/21/18 - Findings from University of KwaZulu-Natal Provide New Insights into Drug Delivery Systems (Novel DNA Aptamers Against CCL21 Protein: Characterization...
By a News Reporter-Staff News Editor at AIDS Weekly Researchers detail new data in Drugs and Therapies- Drug Delivery Systems. According to news reporting from Durban, South Africa, by NewsRx journalists, research stated, "The chemokine ligand 21 is a cytokine that attracts CCR7-positive cells to the T cell zone of lymph nodes by directional migr
5/21/18 - Lannett Receives FDA Approval For Dronabinol Capsules
Lannett Company, Inc. today announced that it received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Dronabinol Capsules USP, 2.5 mg, 5 mg and 10 mg, the therapeutic equivalent to the reference listed drug, Marinol Capsules 2.5 mg, 5 mg and 10 mg of AbbVie Inc. For the 12 months ended March 201
5/21/18 - Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration
By a News Reporter-Staff News Editor at Pharma Business Week Lipocine Inc., a specialty pharmaceutical company, announced that it has received a Complete Response Letter from the United States Food and Drug Administration regarding its New Drug Application for TLANDO?, the Company's oral testosterone product candidate for testosterone replaceme
5/21/18 - Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT
By a News Reporter-Staff News Editor at Clinical Trials Week Medicure Inc. is pleased to announce the commencement of enrollment in SAVI-PCI a prospective, multicenter, randomized clinical trial of its commercial product, AGGRASTAT , in the United States. The first sites initiated in the SAVI-PCI study are the Centennial Heart and Vascular Cent
5/21/18 - New Diabetes Mellitus Management Study Findings Have Been Reported by Investigators at Copenhagen University Hospital (Parenteral nutrition and...
New Diabetes Mellitus Management Study Findings Have Been Reported by Investigators at Copenhagen University Hospital. According to news reporting originating in Copenhagen, Denmark, by NewsRx journalists, research stated, "Pancreatogenic diabetes develops in patients undergoing total pancreatectomy and complicates post-surgical management.
5/21/18 - Patent Issued for Methods, Compounds, and Compositions for Inhibition of ROS (USPTO 9963452)
By a News Reporter-Staff News Editor at Pharma Business Week A patent by the inventors Grueneberg, Dorre A.; Kalid, Ori; Xian, Jun; Rajur, Sharanappa B.; Kim, Hwa-Ok; Neelagiri, Venugopal Rao; Salgaonkar, Paresh; Sethumadhavan, Divakaramenon; Moon, Chaeho; Neelagiri, Madhavi, filed on March 13, 2014, was published online on May 8, 2018, according
5/21/18 - Patent Issued for Microarray for Delivery of Therapeutic Agent, Methods of Use, and Methods of Making (USPTO 9962534)
By a News Reporter-Staff News Editor at Pharma Business Week A patent by the inventors Chen, Guohua; Ding, Zhongli; Ghartey-Tagoe, Esi; Shastry, Ashutosh; Worsham, Robert Wade; Singh, Parminder, filed on March 14, 2014, was published online on May 8, 2018, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents
5/21/18 - Patent Issued for Safety Device for a Pre-Filled Syringe and Injection Device (USPTO 9962499)
By a News Reporter-Staff News Editor at Pharma Business Week Sanofi has been issued patent number 9962499, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Roberts, Gareth; Ward, Chris; Ekman, Matthew. This patent was filed on April 13, 2016 and was published online on May 8, 2018.
5/21/18 - Pfizer Inc. - LYRICA Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
NEW YORK- Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. The study was a post-marketing requirement by the U.S. Food and Drug Administration. 'The Phase 3 to
5/21/18 - Portal Instruments Chief Executive Officer Patrick Anquetil to Present at 2018 UBS Global Healthcare Conference
Portal Instruments, a medical device company focused on advanced drug delivery and solving the challenge of self-administering biological medicines, is pleased to announce that Chief Executive Officer Patrick Anquetil will present at the 2018 UBS Global Healthcare Conference on Monday, May 21 at 8:30 a.m. ET at the Grand Hyatt New York in New York
5/21/18 - Studies from National Research Center Further Understanding of Drug Delivery Systems (Nanotechnology as a Promising Strategy for Anticancer Drug...
By a News Reporter-Staff News Editor at Clinical Trials Week New research on Drugs and Therapies- Drug Delivery Systems is the subject of a report. According to news reporting out of Cairo, Egypt, by NewsRx editors, the research stated, "Cancer was and still a very stressful and urgent disease condition representing a leading cause of death in de
5/21/18 - Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps
The Department of Ear Nose& Throat/Allergy at Summit Medical Group was part of a clinical trial that led the U.S. Food& Drug Administration to approve XHANCE?, a nasal spray for the treatment of nasal polyps in patients 18 years of age or older. In the past, medications have not been completely effective and even when patients have surgery to r
5/20/18 - Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
Takeda Pharmaceutical Company Limited today announced that the company will feature a total of 14 Takeda Oncology-sponsored presentations at two upcoming medical meetings: the 54th Annual Meeting of the American Society of Clinical Oncology, June 1-5 in Chicago and the 23rd Congress of the European Hematology Association, June 14-17 in Stockholm.
5/19/18 - Adheriums Technology Used for Large Scale Electronic Data Capture in Landmark Mild-Asthma Trials [Kuwait News Agency]
-Adherium, a digital health company that improves medication adherence and patient outcomes, announced the extensive use of its Hailie technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal of Medicine and will be presented this weekend at the American Thoraci
5/19/18 - Implantable Drug Delivery Devices Market Stood at US $11.6 Bn in 2011 and Is Predicted to Reach US $21.1 Bn by 2018
Albany, NY 05/18/2018 A new Transparency Market Research report states that the global implantable drug delivery devices market stood at US $11.6 bn in 2011 and is predicted to reach US $21.1 bn by 2018. It is predicted to expand at a CAGR of 8.80% from 2012 to 2018. The title of the report is "Implantable Drug Delivery Devices Market- Global
5/19/18 - Parenteral Drug Delivery: Optimizing and Developing Novel Methods in PFS Industry- Updates at SMi Event
Pre-Filled Syringes West Coast: SMi Groups latest installment in the industry renowned Pre-Filled Syringes global event series welcoming industry leaders this June in San Diego, USA.
5/19/18 - Pfizers Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial [Tehran Times (Iran)]
Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age. The study was a post-marketing requirement by the U.S. Food and Drug Administration. Pfizer internal medicine
5/18/18 - Adherium's Technology Used for Large ScaleElectronic Data Capture in Landmark Mild-Asthma Trials
Adherium, a digital health company that improves medication adherence and patient outcomes, announced the extensive use of it s Hailie? technology in two landmark clinical trials investigating the treatment of mild asthma, which have just been published in the New England Journal of Medicine and will be presented this weekend at the American
5/18/18 - AGILE THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
The Company had the Type A Meeting to discuss the complete response letter dated December 21, 2017 that the FDA issued in connection with the June 26, 2017 New Drug Application resubmission for the Company's investigational low dose, non-daily combination hormonal contraceptive patch, Twirla. The Company received the final meeting minutes from the
5/18/18 - Agile Therapeutics, Inc. Provides Regulatory Update on Twirla (AG200-15) for the Prevention of Pregnancy
Agile Therapeutics, Inc.,, a women s healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration held on April 16, 2018 to discuss the complete response letter issued by the FDA on December 21, 2017 relating to the New Drug Application for Twirla, the Company s i
5/18/18 - Amneal Launches Generic for Sabril: Vigabatrin for Oral Solution, USP
By a News Reporter-Staff News Editor at Drug Week Amneal Pharmaceuticals has launched vigabatrin for oral solution USP, a generic equivalent for Sabril . Amneal has also filed an ANDA with US FDA for the tablet form of vigabatrin. Annual U.S. sales of vigabatrin for oral solution were $318 million, according to March 2018 IQVIA? market data.
Articles(s): 1 - 25 of 93     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415